A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 68 |
| Updated: | 8/4/2016 |
| Start Date: | March 2010 |
| End Date: | June 2014 |
This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d
supplementation in schizophrenia patients with mild or greater negative symptoms.
L-methylfolate, a prescription medical food, is the activated form of folate required for
conversion of homocysteine to methionine and hence is the optimal form of folate for
supplementation, since it eliminates the need for activation by MTHFR. The purpose of this
study is to examine the change in plasma L-methylfolate concentrations following a
three-month trial of L-methylfolate 15 mg/d compared to placebo.
supplementation in schizophrenia patients with mild or greater negative symptoms.
L-methylfolate, a prescription medical food, is the activated form of folate required for
conversion of homocysteine to methionine and hence is the optimal form of folate for
supplementation, since it eliminates the need for activation by MTHFR. The purpose of this
study is to examine the change in plasma L-methylfolate concentrations following a
three-month trial of L-methylfolate 15 mg/d compared to placebo.
Blood levels of L-methylfolate and biological activity will be evaluated by examining
changes in plasma homocysteine concentrations, serum methionine concentrations and changes
in brain activation as measured by fMRI.
changes in plasma homocysteine concentrations, serum methionine concentrations and changes
in brain activation as measured by fMRI.
Inclusion Criteria:
- Diagnosis of schizophrenia, any subtype
- Male of female
- Age 18-68 years
- Treated with an antipsychotic for at least 6 months at a stable dose for at least 6
weeks
- PANSS total score of at least 60, with at least 3 (moderate) on one negative symptom
item or on one positive symptom item
- Simpson Angus Scale (SAS) for the EPS total score of 12 or less and
- A score of 2 (mild) or less on all items of the Calgary Depression Rating Scale
(CDRS)
- Comprehension of English adequate to complete cognitive testing
Exclusion Criteria:
- Unable to provide informed consent
- CBC results consistent with megaloblastic anemia
- Serum creatinine concentration greater than 1.4
- Current use of folate supplementation > 400mcg folate
- Alcohol or other substance abuse within 3 months (nicotine allowed)
- Current use of any of the following medications: phenobarbital, phenytoin,
carbamazepine, valproic acid, fosphenytoin, primidone or pyrimethamine
- Positive baseline urine toxic screen, (positive test for PCP, barbiturates,
cannabinoids, amphetamines, benzodiazepines, opiates, or cocaine)
- Unstable medical illness (exclusionary lab values are listed in Appendix A)
- Unstable psychiatric illness
- Seizure disorder
- Pregnant or nursing, or planning/trying to get pregnant within the next 6 months, and
- DSM-IV diagnosis of major depressive disorder
We found this trial at
1
site
Boston, Massachusetts
Click here to add this to my saved trials
